JP2021521822A - インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 - Google Patents

インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 Download PDF

Info

Publication number
JP2021521822A
JP2021521822A JP2020559408A JP2020559408A JP2021521822A JP 2021521822 A JP2021521822 A JP 2021521822A JP 2020559408 A JP2020559408 A JP 2020559408A JP 2020559408 A JP2020559408 A JP 2020559408A JP 2021521822 A JP2021521822 A JP 2021521822A
Authority
JP
Japan
Prior art keywords
fusion protein
subunit
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020559408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521822A5 (enExample
Inventor
フー，ヤン−シン
ペン，フア
シェ，ディユアン
Original Assignee
イミューン ターゲティング インク．
イミューン ターゲティング インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューン ターゲティング インク．, イミューン ターゲティング インク． filed Critical イミューン ターゲティング インク．
Publication of JP2021521822A publication Critical patent/JP2021521822A/ja
Publication of JP2021521822A5 publication Critical patent/JP2021521822A5/ja
Priority to JP2024197045A priority Critical patent/JP2025032113A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020559408A 2018-04-25 2019-04-24 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 Pending JP2021521822A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024197045A JP2025032113A (ja) 2018-04-25 2024-11-11 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810376920.1A CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体
CN201810376920.1 2018-04-25
PCT/US2019/028933 WO2019209965A2 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024197045A Division JP2025032113A (ja) 2018-04-25 2024-11-11 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法

Publications (2)

Publication Number Publication Date
JP2021521822A true JP2021521822A (ja) 2021-08-30
JP2021521822A5 JP2021521822A5 (enExample) 2022-05-02

Family

ID=68294664

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559408A Pending JP2021521822A (ja) 2018-04-25 2019-04-24 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法
JP2024197045A Pending JP2025032113A (ja) 2018-04-25 2024-11-11 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024197045A Pending JP2025032113A (ja) 2018-04-25 2024-11-11 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法

Country Status (9)

Country Link
US (1) US12473337B2 (enExample)
JP (2) JP2021521822A (enExample)
KR (1) KR20210024446A (enExample)
CN (2) CN110396133B (enExample)
AU (1) AU2019261411B2 (enExample)
BR (1) BR112020021791A2 (enExample)
CA (1) CA3097995A1 (enExample)
EA (1) EA202092459A1 (enExample)
WO (1) WO2019209965A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
EP4251187A4 (en) * 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
WO2022129313A1 (en) * 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Precursor proteins and kit for targeted therapy
WO2022204267A1 (en) * 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
WO2022226073A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides and methods of use thereof
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
AU2024207005A1 (en) * 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4695282A1 (en) 2023-04-12 2026-02-18 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
CN122349538A (zh) * 2023-12-07 2026-07-07 上海药明生物技术有限公司 针对il-12受体的异二聚体蛋白
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025256578A1 (zh) * 2024-06-12 2025-12-18 龙启生物制药(杭州)有限公司 Treg细胞靶向IL12融合蛋白及其制备、治疗方法
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020062A1 (en) * 1995-12-01 1997-06-05 University Of Massachusetts Il-12 p40 subunit fusion polypeptides and uses thereof
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
US20080311655A1 (en) * 1997-12-08 2008-12-18 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
JP4718274B2 (ja) 2005-08-25 2011-07-06 東京エレクトロン株式会社 半導体製造装置，半導体製造装置の流量補正方法，プログラム
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN105218682B (zh) * 2015-10-26 2019-05-07 杨晶 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020062A1 (en) * 1995-12-01 1997-06-05 University Of Massachusetts Il-12 p40 subunit fusion polypeptides and uses thereof
US20080311655A1 (en) * 1997-12-08 2008-12-18 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOIMMUNOLOGY, vol. 7, no. 7, JPN6023019096, 6 March 2018 (2018-03-06), pages 1 - 13, ISSN: 0005057114 *

Also Published As

Publication number Publication date
CN110396133B (zh) 2021-07-23
CN110396133A (zh) 2019-11-01
WO2019209965A3 (en) 2019-12-05
KR20210024446A (ko) 2021-03-05
WO2019209965A2 (en) 2019-10-31
US20220162280A1 (en) 2022-05-26
EA202092459A1 (ru) 2021-06-15
CN112638938A (zh) 2021-04-09
JP2025032113A (ja) 2025-03-11
EP3810639A2 (en) 2021-04-28
AU2019261411B2 (en) 2024-11-14
CA3097995A1 (en) 2019-10-31
AU2019261411A1 (en) 2020-11-26
US12473337B2 (en) 2025-11-18
BR112020021791A2 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
AU2019261411B2 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
JP7684047B2 (ja) インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
JP3652582B2 (ja) タイプｉｉインターロイキン−１受容体
CA2919725C (en) An il-15 and il-15r.aplha. sushi domain based modulokines
JP2023503868A (ja) インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法
AU2023200875A1 (en) UTI fusion proteins
CN118451096A (zh) 异二聚体fc细胞因子及其用途
AU2021202787A1 (en) Combination therapy for the treatment of cancer
WO2022015711A1 (en) Fusion proteins of anti-pd-l1 and attenuated interferon, and compositions and therapeutic methods thereof
WO1997020062A1 (en) Il-12 p40 subunit fusion polypeptides and uses thereof
CN114456274A (zh) 抗Her-2抗体-趋化因子融合蛋白及其制法和应用
US20260070957A1 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
HK40050873A (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
HK40050872A (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
TW202540162A (zh) 含有結合至cldn18.2和cd3之雙特異性結合劑和抗vegfr2抗體之組合療法
JP2006501839A (ja) Ｉｌ−１８ｂｐのプロモーター、その製造および使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241223